The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™, a new antibiotic combination developed to treat complicated intra-abdominal infections caused by drug-resistant bacteria. This approval marks a significant step forward in combating antimicrobial resistance (AMR), a growing global health concern. EMBLAVEO™ is specifically designed to target bacteria that have become resistant to many existing antibiotics, offering a much-needed treatment option for patients facing limited choices in managing severe infections.
Diabetic emergencies remain a significant healthcare challenge in developing countries, presenting a complex intersection of medical, social, and economic issues. This systematic review highlights the concerning prevalence and impact of acute diabetic complications in resource-limited settings.
This systematic review and meta-analysis investigated the effectiveness of triple therapy combinations for treating uncontrolled asthma in adults, with a particular focus on comparing a single inhaler containing beclometasone, formoterol, and glycopyrronium (BDP/FOR/GLY) against other triple therapy options.
The MeMeMe randomized trial studied whether metformin (1,700 mg/day), with or without a Mediterranean diet (MedDiet), could reduce the incidence of major noncommunicable diseases (NCDs) in individuals with metabolic syndrome (MetS). The trial included 1,442 participants, randomly assigned to one of four groups: metformin alone, metformin + MedDiet, placebo alone, or placebo + MedDiet. The participants were followed for an average of three years, with the primary outcome being the cumulative incidence of type 2 diabetes, cardiovascular diseases, and cancer.
Vertex Pharmaceuticals has recently achieved two significant FDA approvals in just 41 days. On December 20, 2024, the FDA approved Alyftrek for treating cystic fibrosis (CF), followed by the approval of Journavx, a novel treatment for moderate-to-severe acute pain, just a few days later.
